Movement Alert｜Eli Lilly Intraday Rise 3.02% in Regular Trading, Breast Cancer Combination Trial Collaboration Supports Sentiment

Market Focus10-14 21:40

On October 14, Eli Lilly rose 3.02% in regular trading, with shares trading around $1200.375 and turnover of $235 million.

The clearest catalyst in public disclosures was a newly announced clinical trial collaboration with Prelude Therapeutics to study Prelude's PRT13722 in combination with Eli Lilly's breast cancer medicines abemaciclib and imlunestrant.

Prelude said the US Food and Drug Administration cleared the investigational new drug application, with the phase 1 breast cancer study expected to begin enrollment in Q4. The trial will start with PRT13722 as a monotherapy before moving into combination cohorts. The update adds to Eli Lilly's recent oncology pipeline momentum, while broader sentiment has also been supported by analyst expectations for strong third-quarter volume growth and a possible guidance increase ahead of the company's October 29 results.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment